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A B S T R A C TObjectives: We determined how Israeli oncologists and family physi-
cians value life-prolongation versus quality-of-life (QOL)-enhancing
outcomes attributable to cancer and congestive heart failure inter-
ventions. Methods: We presented physicians with two scenarios
involving a hypothetical patient with metastatic cancer expected to
survive 12 months with current treatment. In a life-prolongation
scenario, we suggested that a new treatment increases survival at
an incremental cost of $50,000 over the standard of care. Participants
were asked what minimum improvement in median survival the new
therapy would need to provide for them to recommend it over the
standard of care. In the QOL-enhancing scenario, we asked the
maximum willingness to pay for an intervention that leads to the
same survival as the standard treatment, but increases patient’s QOL
from 50 to 75 (on a 0–100 scale). We replicated these scenarios by
substituting a patient with congestive heart failure instead of meta-
static cancer. We derived the incremental cost-effectiveness ratio per
quality-adjusted life-year (QALY) gained threshold implied by eachsee front matter Copyright & 2013, International S
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siness and Management, Ben-Gurion University oresponse. Results: In the life-prolongation scenario, the cost-
effectiveness thresholds implied by oncologists were $150,000/QALY
and $100,000/QALY for cancer and CHF, respectively. Cost-
effectiveness thresholds implied by family physicians were $50,000/
QALY regardless of the disease type. Willingness to pay for the QOL-
enhancing scenarios was $60,000/QALY and did not differ by physi-
cians’ specialty or disease. Conclusions: Our ﬁndings suggest that
family physicians value life-prolonging and QOL-enhancing interven-
tions roughly equally, while oncologists value interventions that
extend survival more highly than those that improve only QOL. These
ﬁndings may have important implications for coverage and reim-
bursement decisions of new technologies.
Keywords: cancer, cost-effectiveness, heart failure, quality of life,
willingness to pay.
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Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Among health interventions, the cost of cancer treatment has
received increased attention in the last decade mainly because of
the very high treatment costs associated with newly developed
chemotherapies and biological drugs. The debate over cancer
drugs has focused not only on the costs of treatments but also on
their relatively modest beneﬁts, as many new drugs, such as
those targeted at patients with metastatic disease, produce
relatively small gains in life expectancy or quality of life (QOL) [1].
Coverage decisions on new technologies may be based on
society’s willingness to pay (WTP) for a life-year or a quality-
adjusted-life-year (QALY) gained, using an implicit or explicit cost-
effectiveness ratio to determine value for money. Acknowledging
the unique circumstances of end-of-life care, several jurisdictions
have adopted special mechanisms for coverage and reimbursementdecisions on cancer drugs. Reimbursement agencies tend to use
more ﬂexible criteria to value cancer drugs, even when their cost-
effectiveness ratio is higher than the implicit or explicit threshold
that determines “good value for money” [2].
Practicing oncologists are frequently on the front line of this
controversy, having to decide whether to offer their patients
new and expensive treatments, sometimes not included in the
health insurance beneﬁts package. Recently, several studies
from the United States and Canada have explored the implicit
cost-effectiveness ratios that oncologists used to determine
whether an intervention provides good value for money [3–7].
The ﬁndings suggest that oncologists are willing to prescribe
treatments with a substantially higher (unfavorable) cost-
effectiveness ratio for life-prolonging compared with interven-
tions that improve only patients’ QOL. These surveys, however,
have not examined whether physicians place a higher value onociety for Pharmacoeconomics and Outcomes Research (ISPOR).
Systems Management, Faculty of Health Sciences and Guilford
f the Negev, PO Box 653, Beer-Sheva 84105, Israel.
Box 1–Life-prolonging scenario
Imagine that large randomized phase III trials have
shown that a new cancer medication (treatment for
congestive heart failure NYHA class IV) increases
survival in first-line treatment of patients with sympto-
matic metastatic cancer (congestive heart failure NYHA
class IV). Side effects of the new treatment and the
existing treatment are roughly equivalent, but a formal
QOL evaluation was not performed. The total cost of the
standard treatment over the course of therapy is $25,000
and leads to a median survival of 12 months. The total
cost of the new medication (treatment) over the course
of therapy is $75,000.
What minimum improvement in median survival (in
months) over standard treatment’s median survival
would cause you to recommend the new medication
(treatment) instead of standard treatment? (Assume
that patients bear no direct costs for the medication).
Box 2–QOL-enhancing scenario
Imagine that the standard-of-care drug in the first-line
treatment of patients with symptomatic metastatic
cancer (congestive heart failure NYHA class IV) leads
to a median survival of 12 months. Patients treated with
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 8 4 2 – 8 4 7 843cancer care as compared with care for other life-threatening
conditions.
Indeed, advanced congestive heart failure (CHF) is similar to
metastatic cancer, in that both are life-threatening medical
conditions. Although drug therapy for CHF may be substantially
cheaper than cancer drugs, the cost of several implantable
devices such as left ventricular assist devices and cardiac
resynchronization therapy devices may exceed US $100,000 and
their cost-effectiveness remains uncertain [8,9].
Similar to oncologists, family physicians may also be involved
in their patients’ decisions about whether to opt for care of very
costly treatments, sometimes with only low potential beneﬁts.
Because they are exposed to a wide variety of medical conditions
and perhaps because of other factors, family physicians may have
different and broader views on the cost-effectiveness of health
interventions than those possessed by oncologists. In this study,
we explore the implicit incremental cost-effectiveness ratio sug-
gested by oncologists and family physicians in Israel, for both life-
prolonging and QOL-enhancing outcomes attributable to innova-
tive cancer and CHF interventions. On the basis of results from
previous analyses [3,4], we hypothesized that physicians would
value life-prolonging interventions higher than QOL-enhancing
ones and that the implied cost-effectiveness ratio would be higher
for cancer interventions than for interventions for heart failure,
due to a “cancer premium,” suggesting that individuals grant
cancer treatments special status and would be willing to pay more
for cancer treatments than for other interventions.the standard-of-care drug experience an average score
of 50 (on a 0–100 QOL scale).
The total cost of the standard treatment over the
course of 1 year is $25,000.
Imagine that large randomized phase III trials have
shown that a new cancer medication (congestive heart
failure NYHA class IV treatment) for the same indication
leads to the same survival as the standard treatment,
but results in a statistically and clinically significant
improvement in QOL, improving it from a score of 50 to
75 on the same 0 to 100 scale.
At what additional cost (in thousands of dollars) per
year of treatment would you recommend the new
medication (treatment) instead of the standard treat-
ment? (Assume that patients bear no direct costs for the
medication.)Methods
The Hypothetical Clinical Scenarios
Each oncologist and family physician was asked to consider four
hypothetical clinical scenarios (Boxes 1 and 2). The scenarios relating
to cancer treatment were adapted from previous surveys [3–7].
The life-prolonging scenario (Box 1) involved a patient with
metastatic cancer expected to survive 12 months with standard
medical treatment at an annual cost of $25,000. We then
presented respondents with a scenario describing a new treat-
ment at a total cost of $75,000 (incremental cost of $50,000 over
the standard of care). Physicians were asked what minimum
improvement in median survival (in terms of months of survival
gain) the drug would need to provide for them to recommend it
over the standard of care. The physicians were asked to assume
that the patient does not bear direct cost/co-payment for the
medication. We replicated this scenario with similar details, but
substituting a patient with CHF (New York Heart Association
[NYHA] class IV) instead of metastatic cancer.
The QOL-enhancing scenario (Box 2) involved a second patient
with metastatic cancer, expected to survive 12 months with
standard medical treatment at an annual cost of $25,000. The
QOL of this patient (on a 0–100 scale, with 0 representing the
worse QOL and 100 the best QOL) was assumed to be 50.
Physicians were asked to indicate the highest cost at which they
would recommend a new medication that would increase the
patient’s QOL from 50 to 75 on the same scale, but would have no
impact on the patient’s survival. As in the life-prolongation
scenario, we replicated this scenario for a patient with CHF.
To assess oncologists’ and family physicians’ general atti-
tudes toward the cost of cancer and CHF care, we further asked,
“what do you think is a reasonable deﬁnition of ‘good value for
money’ or cost-effectiveness ratio per life-year gained (regardless
of patient’s QOL) in cancer care? (and CHF care)?” Finally, we
collected demographic information and medical training and
practice characteristics.Study Population and Survey Methods
We sent the questionnaire to 156 board-certiﬁed oncologists in
Israel with a valid e-mail address and to a randomly selected
sample of 300 board-certiﬁed family physicians received from the
Israel Association of Family Physicians. The list of oncologists
was compiled on the basis of the directory of the Israeli Society of
Clinical Oncology and Radiotherapy and from the list of physi-
cians practicing in general medical centers and in Israel’s four
health plans.
The survey questionnaire was developed and distributed by
using the Qualtrics Online Survey Software (Qualtrics Labs, Inc.,
Provo, UT). Participants received an e-mail invitation to complete
the Web-based questionnaire and a personal link to the ques-
tionnaire. To avoid ordering bias, each participant received and
answered the above-mentioned scenarios in a random order (i.e.,
they could receive the cancer-related or the CHF scenarios ﬁrst).
The study was approved by the ethics committee of the
Faculty of Health Sciences of Ben-Gurion University of the Negev.
Data Analysis
The primary outcome measurers of the presented scenarios are
the incremental cost-effectiveness ratio (ICER) implied by each
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calculated as follows:
ICER ¼ Number of months of additional survival
50,000 12 months
Thus, a respondent who indicated that the minimum im-
provement in median survival needed to recommend a treatment
at an incremental cost of $50,000 (i.e., $75,000 for the new
treatment vs. $25,000 for the standard of care) would be 6 months
implicitly endorses an ICER of $100,000 per QALY gained ([$50,000
 12]/6) ¼ $100,000.
We also calculated the implied ICER for the QOL-enhancing
scenario, with the new treatment increasing the patient’s QOL by
25 points (from 50 to 75) over the standard of care, thus providing
one quarter of a QALY. To produce the ICER, the incremental cost
indicated by the respondent is divided by 0.25.
ICER ¼ Incremental cost of treatment
0:25 QALYs
To illustrate, a physician indicating that she or he will recom-
mend the new treatment at an additional cost of $50,000 implies
an ICER of $200,000 per QALY gained ($50,000: 0.25 ¼ $200,000).
Responses were provided in the form of ranges, and ICERs wereTable 1 – Physicians’ characteristics.
Characteristics Oncologist
Age (y), mean ± SD 54.6 ±
Gender (%)
Female 50
Male 50
Years (mean ± SD) of work experience in medicine 28.6 ±
Medical school (%)
Israel 48
Western Europe and America 13
Eastern Europe 27
Other 12
Fellowship in the United States (%) 39
Additional graduate-level training (%)
Health administration/public health 2
Masters/PhD in basic sciences 8
Other
Employment type (%)
Salaried
Self-employed
Salaried and self-employed
Other
Main practice setting
Health plan (HMO) 6
Public hospital 86
Private hospital 6
Other 2
Type of cancer treated (%)
Breast 58
Gastrointestinal 56
Lung 37
Genitourinary 29
Gynecologic 21
Head and neck 21
Sarcoma 21
Melanoma 14
Hematologic 4
Other 8
HMO, health maintenance organization; NS, not signiﬁcant.
 Not mutually exclusive.calculated at the midpoint value of each range (e.g., for $20,000–
$40,000, the midpoint of $30,000 was considered).
Differences in physicians’ judgments of good value for money
and physicians’ training characteristics were assessed by using
chi-square tests. Differences in oncologists’ and family physi-
cians’ implied cost per QALY thresholds in each scenario were
assessed by using independent-sample t tests, and differences
between each physician sample responses to cancer and CHF
scenarios were assessed by using paired-sample t tests. All
analyses were performed by using PASW Statistics 18. P values
of less than 0.05 were considered statistically signiﬁcant for all
comparisons.Results
Physician Characteristics
We received responses from 52 oncologists and 116 family
physicians for overall response rates of 36% and 39%, respec-
tively. Respondent demographic and medical training character-
istics are presented in Table 1. Approximately 50% of the
respondents were male; oncologists were on average older thans (n = 52) Family physicians (n = 116) P
10.8 50.1 ± 9.2 0.006
.0 51.7
.0 48.3 NS
11.2 23.1 ± 9.5 0.001
57
16
24
3 NS
6 o0.001
11
3
7
64
7
27
3
91
2
0
7
Table 2 – Cost per QALY implied for life-prolonging and QOL-enhancing interventions.
Life-prolonging scenario
Cancer Heart failure P
Oncologists (n ¼ 52)
Minimum number of months, mean  SD 6.12  5.48 7.52  6.07 0.029
Minimum number of months: median (range) 4.0 (2–24) 6.0 (2–24)
Cost/QALY implied ($), median 150,000 100,000
Cost/QALY implied ($), 5% trimmed mean 164,830 131,766 0.001
Family physicians (n ¼ 116)
Minimum number of months, mean  SD 13.13  11.70 13.19  10.8 NS
Minimum number of months, median range 12.0 (1–60) 12.0 (1–60)
Cost/QALY implied ($), median 50,000 50,000
Cost/QALY implied ($), 5% trimmed mean) 72,537 66,950 NS
P† o0.0001 o0.0001
QOL-enhancing scenario
Oncologists (n ¼ 52)
Cost/QALY implied ($), median 60,000 60,000
Cost/QALY implied ($), 5% trimmed mean 80,299 82,949 NS
Family physicians (n ¼ 116)
Cost/QALY implied ($), median 60,000 60,000
Cost/QALY implied ($), 5% trimmed mean 100,230 95,920 NS
P† NS NS
NS, not signiﬁcant; QALY, quality-adjusted life-year; QOL, quality of life.
 Paired-sample t test.
† Independent-sample t test.
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medical practice, and approximately 40% had fellowship training
in the United States. Only very few physicians had advanced
training in health policy and management or in public health. For
oncologists, breast and gastrointestinal cancers were the most
frequently treated types of cancer, similar to ﬁndings from North
American oncologists [4].Cost-Effectiveness Ratios
Life-prolonging scenario
The median value of minimum improvement in patient survival
to justify the new cancer drug at an incremental cost of $50,000
suggested by oncologists was 4 months, and the corresponding
value for a CHF intervention was 6 months. These values
imply that oncologists value a QALY in cancer care at $150,000
and at $100,000 in CHF interventions (Table 2). Among family
physicians, the corresponding values were 12 months for
both cancer and CHF interventions, implying an endorsement
of a cost-effectiveness threshold of $50,000 per QALY. We report
both the 5% truncated mean and median values, because
the truncated mean is less sensitive to outliers and provides a
more valid estimate of the mean values. Because results were
skewed, we used medians for presenting cost-effectiveness
thresholds.QOL-enhancing scenario
The mean and median WTP values for a QALY in the QOL-
enhancing scenarios are presented in Table 2. The median WTP
for an improvement of 0.25 QALYs was $15,000, implying a cost-
effectiveness ratio of $60,000 per QALY, and was the same
between cancer and CHF interventions and between oncologists
and family physicians. As in the life-prolonging scenario, we also
report the 5% truncated means and median values.Value for money
Oncologists, on average, implicitly endorsed higher cost-
effectiveness ratios than did family physicians for both cancer
and CHF interventions: $50,000 to 75,000 and $25,000 to 50,000,
respectively. On the basis of ﬁndings from a previous study [5],
we expected that the average implied cost-effectiveness thresh-
olds would increase for respondents who selected higher values
to present good value for money. Indeed, the derived thresholds
were generally higher for those respondents who selected higher
deﬁnitions for good value for money (Fig. 1).Discussion
The purpose of our study was to explore whether Israeli physi-
cians place a higher value on life-prolonging versus QOL-
enhancing treatments, and whether these values vary between
oncologists and family physicians. When asked to consider the
cost of treatment in recommending a new medication over the
standard of care, oncologists placed a signiﬁcantly higher value
per QALY on life-prolonging treatments than on QOL-enhancing
interventions for both scenarios involving patients with cancer
and CHF. These results are consistent with a previous survey
conducted in the United States. On average, U.S. oncologists
implied that they were willing to prescribe treatments that cost
approximately $250,000 per QALY in life-prolonging situations
versus only $120,000 for treatments that improved the QOL but
did not prolong patients’ life expectancy [4]. However, when
asked directly to deﬁne what a good value for money is, the
majority of oncologists in the United States and Canada endorsed
cost-effectiveness ratios below $100,000 per life-year gained [5].
Similar ﬁndings were found in our survey of Israeli oncologists;
when asked directly about appropriate value for money thresh-
olds, approximately 90% of the physicians endorsed a cost-
effectiveness ratio of less than $100,000 per life-year gained with
a median range endorsed of $50,000 to 75,000. While the value for
0–25K 25–50K 50–75K 75–100K
0–25K 25–50K 50–75K 75–100K
Fig. 1 – Implied cost-effectiveness ratios ($/QALY) as a function of perceived “reasonable value-of-life year” as implied by
cancer and CHF life-prolonging scenarios. CHF, congestive heart failure; QALY, quality-adjusted life-year.
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 8 4 2 – 8 4 7846a QALY in the QOL-enhancing scenario ($60,000 per QALY gained)
was within this range, the value placed on a QALY in the life-
prolonging scenario was twofold higher. Our ﬁnding suggest that
at least in the view of oncologists the “quality” in the QALY
metric is less valued than the “life-year” component of the
metric. In other words, in their view, treatments that extend life
have priority over treatment that can improve only patient’s QOL,
even when both treatments have the same QALY gained. As
argued previously, because of preferences for “rule of rescue,”
life-extending therapies may receive greater priority than other
therapies [10]. Indeed, a survey conducted in the adult population
in Israel found that the rule of rescue was predominant for morethan a quarter of the population, even when death was only
marginally postponed [11].
As opposed to the views expressed by oncologists, family
physicians’ responses implied substantially lower cost-
effectiveness thresholds for both cancer and CHF care in the
life-prolonging scenario. The value they placed on a QALY in
the QOL-enhancing scenarios, however, was similar to what
was implied by oncologists. These results may have several
explanations. First, oncologists deal with high-cost and some-
times experimental medical interventions on a daily basis and
may be more frequently involved in their patients’ decisions
to opt for expensive care, even in cases in which these
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 8 4 2 – 8 4 7 847interventions are associated with only a marginal beneﬁt and
are not covered by health insurance. Although family physi-
cians are exposed to various types of medical conditions
affecting their patients, they usually are not directly involved
in the decision-making process in patients at advance stages
of the disease because this care is usually provided in high-
cost specialty care in tertiary medical centers rather than in
the community.
Second, family physicians may also have a better perception
of the cost implications of new medical interventions, and may
be better prepared to deal with budget constraints and allocation
of limited resources between competing needs. Although physi-
cians are generally not prepared to interpret ﬁndings from cost-
effectiveness analyses, our ﬁndings suggest that the proportion
of family physicians with graduate training in health adminis-
tration and public health is substantially higher than among
oncologists. Our data suggest that the cost-effectiveness ratios
implied by family physicians with additional training in health
policy and management may be lower compared with physicians
who did not have such training. Because of the relatively small
sample size, however, these differences in judgments were not
statistically signiﬁcant. Finally, the physician groups surveyed
are different in other characteristics (i.e., age and experience in
medical practice, and fellowship training in the United States, a
privately based health care system) that may explain some of the
discrepancy.
Our study has several limitations. First, the initial sample size
was somewhat small compared with previous surveys of this
kind conducted in the United States and Canada [3–7]. The
modest response rate, despite our major efforts to contact and
encourages physicians to respond to the survey, might mean that
our results may be subject to response bias. Nevertheless, despite
the relatively low number of respondents, we were able to
identify important differences between cancer and CHF treat-
ments, as well as between life-prolongation and QOL-enhancing
interventions. Second, we presented physicians with two scenar-
ios presenting either life-prolonging or QOL improvements. These
scenarios may be rather simplistic and do not represent “real-
life” care because many interventions for treating cancer and CHF
affect both quantity and QOL. We separated these potential
beneﬁts to be able to assess whether physicians place a higher
value on life-prolonging interventions. Finally, to allow compar-
isons between the implied cost per QALY ratio in the life-
prolonging and a QOL-enhancing scenario, we assumed in our
analysis that a patient in the life-prolongation scenario main-
tained a full QOL (i.e., 100 on a 0–100 scale). This, of course, is
unrealistic when patients with cancer or CHF are considered.
Alternatively, the implied cost-effectiveness ratios may be per-
ceived as cost per life-year rather than cost per QALY gained.
Notwithstanding these limitations, our study is to our knowl-
edge the ﬁrst attempt to compare values of oncologists and
family physicians regarding cancer and CHF care. As in other
countries, the proportion of the budget allocated to fund new
cancer drugs in Israel is substantial and exceeds other therapeu-
tic areas [12]. This implies that decision makers tend to give a
higher priority to interventions aimed at treating life-threatening
medical conditions. Although the coverage decision process in
Israel does not explicitly use results from cost-effectiveness
analyses [13], studies have suggested that in many cases, the
recommended technologies for inclusion in the National List of
Health Services are those with favorable cost-effectivenessresults [14]. Nevertheless, the value of one life-year gained or
one QALY gained has not yet been determined in Israel.
Many countries and reimbursement agencies, such as the
National Institute of Health and Clinical Excellence in England,
are now debating whether to place higher value on end-of-life
cancer care, and more speciﬁcally, use a higher cost per QALY
threshold to determine coverage for treatments for the terminally
ill [2]. Our study suggests that in the view of family physicians a
QALY is a QALY regardless of the type of disease and its source
(i.e., improvement in life expectancy vs. improvement in QOL).
The main attraction of the cost per QALY measure is its universal
applicability. Making an exception for any group, such as patients
with cancer or life-extending treatment for terminally ill patients,
limits that universality and sets precedent for other groups [15].
Thus, we believe that our ﬁndings should be considered by
decision makers when making resource allocation decisions in
Israel and worldwide.Acknowledgments
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